Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CVM | US
-0.05
-5.26%
Healthcare
Biotechnology
30/06/2024
18/10/2024
0.90
0.98
0.98
0.89
CEL-SCI Corporation a clinical-stage biotechnology company engages in the research development and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine a Leukocyte Interleukin injection which has completed a pivotal Phase 3 clinical trial for patients who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology a patented T-cell modulation process that stimulates the human immune system to fight bacterial viral parasitic infections autoimmune conditions allergies transplantation rejections and cancer. In addition the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna Virginia.
View LessLow Market Beta (-0.4 to 0.8)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
35.9%1 month
42.7%3 months
59.7%6 months
71.7%-
-
6.78
1.43
0.50
-3.71
-
-
-25.52M
55.34M
55.34M
-
-
-
-62.70
-250.20
12.14
7.16
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.22
Range1M
0.33
Range3M
1.33
Rel. volume
1.02
Price X volume
243.46K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Omega Therapeutics Inc. Common Stock | OMGA | Biotechnology | 1.06 | 60.19M | 1.92% | n/a | 483.39% |
Kezar Life Sciences Inc | KZR | Biotechnology | 0.8238 | 60.11M | 0.96% | n/a | 11.69% |
iShares MSCI Brazil ETF USD Acc | CSBR | Biotechnology | 4.42 | 60.08M | -0.45% | n/a | -2140.66% |
Allakos Inc | ALLK | Biotechnology | 0.66 | 58.64M | 1.54% | n/a | 47.30% |
Kronos Bio Inc | KRON | Biotechnology | 0.95 | 57.28M | 2.15% | n/a | 22.03% |
Actinium Pharmaceuticals Inc | ATNM | Biotechnology | 1.82 | 56.70M | 5.81% | n/a | 4.22% |
Affimed N.V | AFMD | Biotechnology | 3.55 | 55.67M | 7.25% | n/a | 0.00% |
CELU | CELU | Biotechnology | 2.51 | 55.18M | -3.46% | n/a | 127.38% |
OncoCyte Corporation | OCX | Biotechnology | 3.13 | 53.56M | 0.32% | n/a | 16.15% |
Atara Biotherapeutics Inc | ATRA | Biotechnology | 9.41 | 53.39M | 0.32% | n/a | -81.03% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.9 | 19.65M | 2.38% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.03 | 18.60M | 5.10% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.538 | 7.80M | -6.65% | 0.03 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2201 | 3.95M | 4.26% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.76M | 1.92% | n/a | 17.32% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.01 | 897.66K | -12.28% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.38 | 0 | 0.37% | 22.53 | 56.33% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.92 | 0 | -8.84% | n/a | 0.00% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4801 | 0 | -10.26% | n/a | 19.98% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.045 | 0 | -2.34% | n/a | 268.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.71 | 0.53 | Cheaper |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 6.78 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 59.74 | 72.80 | Par |
Debt to Equity | 1.43 | -1.23 | Expensive |
Debt to Assets | 0.50 | 0.25 | Expensive |
Market Cap | 55.34M | 3.66B | Emerging |